Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Cancer Research at the
Helen F. Graham Cancer Center
& Research Institute

Tissue Procurement / Tissue Microarray

The Tissue Procurement Center (TPC) at the Helen F. Graham Cancer Center & Research Institute was established in 2003, in collaboration with physicians, staff and the Department of Pathology at ChristianaCare.

The TPC includes a biobank containing more than 4000 frozen and paraffin embedded specimens for future research. Additionally, more than 10,000 tumor and normal paraffin blocks are available from the Department of Pathology. The facility is equipped with a tissue arrayer for generation of tissue microarrays. Additionally, the TPC provides a supply of fresh tissues to local researchers within the Center for Translational Cancer Research as well as the Wistar Institute in Philadelphia, PA. The Graham Cancer Center TPC was one of only three NCI Community Cancer Centers Program sites selected to collect specimens for The Cancer Genome Atlas (TCGA) project. The center employs Open Specimen which allows us to produce barcoded specimen labels, de-identified pathology reports, and a data link to both our data warehouse and tumor registry.

To ensure high quality specimen collection, the procurement process includes a quality control process where control slides are reviewed by the tissue procurement medical director in conjunction with the final surgical pathology slides and report to confirm the diagnosis; the tumor type, percentage of tumor nuclei and necrosis, as well as confirmation that normal tissue is free from contaminating tumor cells is recorded.

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.